Integra LifeSciences (IART) PT Lowered to $26 at Truist Securities

Truist Securities analyst Richard Newitter lowered the price target on Integra LifeSciences (NASDAQ: IART) to $26.00 (from $32.00) while maintaining a Hold rating.

The analyst commented: "Our PT goes to $26 (from $32) based on a ~10x multiple on our 2025E EBITDA. This would represent a ~2x discount to where the company's comp group trades on '25E EBITDA. We think a discount is justified given the accumulating execution errors on the part of the company as well as peers' faster rev/EPS growth prospects, and we think multiple expansion from current levels could be limited over the near-to-intermediate term. Our PT moves lower primarily to reflect our lower '25 ests., while also reflecting a slightly higher comp group valuation since our last update."

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• China e-commerce sees 3% growth in July, recovery expected Macquarie says
• Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral